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A 69-year-old male was admitted to the docu-
mented department due to a transient third-degree 
atrio-ventricular block (AVB) and suspicion of 
infective endocarditis. In the district hospital 
temporary ventricular pacing was applied, and 
vancomycin because of Staphylococcal bacterae-
mia. Two years prior, the patient had undergone 
bioprosthetic valve implantation (St. Jude Medical, 
25 mm) due to complex aortic valve disease, and si-
multaneously had coronary artery bypass surgery.
At hospital admission, the patient was in a good 
general condition with no abnormalities in physi-
cal examination beyond obesity (BMI 37 kg/m2). 
Electrocardiogram (ECG) showed sinus rhythm 
and a complete AVB. Transthoracic (TTE) and 
transesophageal (TEE) echocardiography revealed 
mild left ventricular (LV) systolic dysfunction (LV 
ejection fraction [LVEF] 45%), mildly enlarged left 
ventricle (LV end-diastolic volume 160 mL) and 
moderate degree bioprosthetic aortic regurgitation 
with normal transvalvular gradients (maximum 
20 mmHg), without leaflet perforation or vegeta-
tions. Repeated blood cultures were negative, blood 
tests showed increased C-reactive protein (CRP) 
concentration (Suppl. Table 1), and rifampicin and 
gentamicin were added to vancomycin.
On the 18th day, the patient received perma-
nent epicardial pacing system due to elevated CRP 
concentration (Suppl. Table 1), inconclusive for 
endocarditis TTE and TEE results, and increased 
risk of cardiac device-related infective endocar-
ditis (CDRIE). Because of pericardial adhesions 
after previous cardiac surgery and marked obesity, 
only the epicardial right ventricular lead (Myo-
Dex™1084 T, St. Jude Medical) and VVI pacemaker 
(Vitatron SRG20A1, Medtronic) were implanted. In 
subsequent days, CRP levels decreased (Suppl. 
Table 1), but remained above the reference range.
To confirm or exclude infective endocarditis, 
the patient was referred for 18-fluorine-fluorodeoxy - 
glucose positron-emission-tomography/computed 
tomography (18F-FDG PET/CT), with acquisi-
tion according to standard protocol (Biograph 
40 mCT, Siemens Healthineers). This showed 
a non-homogenous increased uptake around the 
aortic bioprosthesis (Fig. 1A) with maximal stand-
ardized uptake values (SUVmax) up to 5.0. The ratio of 
SUVmax to the mean SUV of liver [SUVr(liver)] was 
1.36, and the ratio of SUVmax to the mean mediasti-
nal blood pool stream SUV [SUVr(MBPS)] was 1.43. On 
this basis, a decision was made to prolong therapy 
with rifampicin and linezolid.
On the 34th day, a hemodynamically unsta-
ble ventricular tachycardia occurred. Another 
18F-FDG PET/CT study was performed, which 
showed decreased metabolic activity around the 
bioprosthetic valve, but without complete resolu-
tion, with SUVmax 3.0, SUVr(liver) 0.98 and SUVr(MBPS) 
1.37 (Fig. 1B). The inflammatory biomarker levels 
in blood tests were within normal range. A decision 
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was made to implant a subcutaneous implantable 
cardioverter-defibrillator (S-ICD), which was 
performed on the 77th day (Emblem S-ICD A209, 
lead 3401, Boston Scientific) (Suppl. Fig. 1). The 
intraoperative defibrillation testing confirmed 
appropriate detection and termination of induced 
ventricular fibrillation.
The second day after implantation, an inappro-
priate shock occurred without any defined reason 
(Suppl. Fig. 2). After consultation with the ICD 
manufacturer, it was speculated that the shock was 
presumably caused by the air being released from 
the connector area. The patient was discharged 
from the hospital on the 84th day and asked to con-
tinue oral linezolid for the next 10 days.
A month later the patient was admitted to the 
documented department because of symptoms of 
LV heart failure. Mildly elevated CRP levels were 
present, but with negative blood cultures. Rifam-
picin and linezolid were administered. TTE and 
TEE showed progression of aortic regurgitation 
with the paravalvular leak, and further LV enlarge-
ment (LV end-diastolic volume 256 mL) and LVEF 
37% (Suppl. Fig. 3). The patient was referred 
for another 18F-FDG PET/CT examination which 
showed moderately increased metabolic activity 
around the aortic valve with SUVmax 4.1, SUVr(liver) 
1.18, and SUVr(MBPS) 1.56 (Fig. 1C). The patient 
was then qualified for surgical treatment. The 
aortic valve bioprothesis was replaced (Medtronic 
29 mm), additionally an epicardial atrial lead was 
implanted (CapSure Epi lead4968, Medtronic) and 
the pacing system was upgraded to dual-chamber 
(Vitatron DRG70A1, Medtronic). Rifampicin and 
linezolid were thereafter continued for 6 weeks. 
Control laboratory tests revealed a gradual de-
crease in the levels of inflammatory markers and 
TTE showed normal aortic valve function and 
LVEF 45%. Two months after the surgery, the 
patient was discharged from the hospital in good 
general condition without antibacterial treat-
ment. During the 2-year observation, the patient 
remained in good condition without significant 
changes in frequent TTE imaging.
Infective endocarditis still remains a challenge 
and is associated with poor prognosis, especially 
in patients with implanted cardiac devices [1]. In 
the present patient, a transient complete AVB 
was the first clinical manifestation of infective 
endocarditis, however repeated echocardiography 
remained inconclusive. It was reported that the use 
of transvenous temporary pacing increases the risk 
of CDRIE [2]. Also, patients with elevated CRP 
concentration at the time of cardiac device implan-
tation may have an increased risk of early compli-
cations requiring transvenous lead removal [3]. 
These were additional factors apart from active 
endocarditis, later confirmed by the 18F-FDG PET/ 
/CT imaging, a finding which supported the epi-
cardial pacing system implantation in this patient. 
Data from the literature indicate that 18F-FDG 
PET/CT is a useful diagnostic tool in challenging 
cases of infective endocarditis, also in patients with 
prosthetic valve endocarditis [4]. The examina-
tion performed before ICD implantation showed 
a decrease in metabolic activity around the aortic 
bioprosthesis. This was the reason for implanting 
the S-ICD. Nevertheless, because of incomplete 
resolution in the 18F-FDG PET/CT imaging at this 
time, despite negative blood cultures, the patient 
should have been referred for cardiac surgery 
instead of implanting the S-ICD. It would have 
eliminated progression of aortic regurgitation and 
cardiac decompensation due to a persistent inflam-
matory process. Also, an inappropriate ICD shock 
could have been avoided. However, the 18F-FDG 
PET/CT showed its usefulness in this case of 
suspected endocarditis. Other advanced echo-
cardiographic techniques, like three-dimensional 
TTE or three-dimensional TEE can be useful 
in the recognition of infective endocarditis. Ad-
ditionally, magnetic resonance imaging can be 
used in the search for extracardiac infectious 
foci, for instance cerebral lesions. In cases of 
inaccessibility 18F-FDG PET/CT imaging these 
techniques should be used to confirm or exclude 
infective endocarditis.
Subcutaneous ICD is a safe and effective 
method in preventing sudden cardiac death with 
a low rate of complications [5, 6]. The inappropriate 
S-ICD shock which occurred in the present patient 
was presumably caused by air being released 
from the connector area. The S-ICD shock due to 
residual air near the S-ICD system (around the 
xiphoid process or the distal part of the electrode) 
has been previously reported [7, 8].
In conclusion, the use of 18F-FDG PET/CT im-
aging is very helpful not only in diagnosis, but also 
in monitoring treatment of infective endocarditis. 
It enables decision making regarding optimal time 
and type of implantable cardiac devices, as well as 
the decision about surgery. 
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Figure 1. The 18-fluorine-fluorodeoxyglucose positron-emission-tomography/computed tomography (18F-FDG PET/CT) 
images obtained from the patient showing changes in metabolic activity around the aortic bioprosthesis; A. After 
initial antimicrobial therapy; B. Before subcutaneous implantable cardioverter-defibrillator implantation; C. During 
the second hospitalization. 
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